Scientists test First-of-its-Kind vaccine to stop pancreatic cancer before it starts
NCT ID NCT05013216
Summary
This early-stage study is testing a new vaccine designed to prevent pancreatic cancer in people at high genetic risk. The vaccine aims to train the immune system to attack cells with a specific cancer-linked mutation. Researchers will enroll 37 participants to check if the vaccine is safe and if it triggers the desired immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.